scholarly journals Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial

2020 ◽  
Vol 26 (2) ◽  
pp. 278-284 ◽  
Author(s):  
Joseph Pidala ◽  
Samantha Jaglowski ◽  
Annie Im ◽  
George Chen ◽  
Lynn Onstad ◽  
...  
Keyword(s):  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Phase Ii Trial ◽  
Chronic Gvhd ◽  
Pilot Phase ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial

2020 ◽  
Vol 26 (9) ◽  
pp. 1612-1619
Author(s):  
Joseph Pidala ◽  
Vijaya R. Bhatt ◽  
Betty Hamilton ◽  
Iskra Pusic ◽  
William A. Wood ◽  
...  
Keyword(s):  
Phase Ii ◽  
Graft Versus Host Disease ◽  
Phase Ii Trial ◽  
Chronic Gvhd ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease

2021 ◽  
Vol 22 (5) ◽  
pp. 2385
Author(s):  
Ethan Strattan ◽  
Gerhard Carl Hildebrandt
Keyword(s):  
Wound Healing ◽  
Mast Cell ◽  
Mast Cells ◽  
Graft Versus Host Disease ◽  
Chronic Gvhd ◽  
Fibrotic Disease ◽  
Acute Leukemias ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host

Allogeneic hematopoietic stem cell transplantation (HSCT) is most commonly a treatment for inborn defects of hematopoiesis or acute leukemias. Widespread use of HSCT, a potentially curative therapy, is hampered by onset of graft-versus-host disease (GVHD), classified as either acute or chronic GVHD. While the pathology of acute GVHD is better understood, factors driving GVHD at the cellular and molecular level are less clear. Mast cells are an arm of the immune system that are known for atopic disease. However, studies have demonstrated that they can play important roles in tissue homeostasis and wound healing, and mast cell dysregulation can lead to fibrotic disease. Interestingly, in chronic GVHD, aberrant wound healing mechanisms lead to pathological fibrosis, but the cellular etiology driving this is not well-understood, although some studies have implicated mast cells. Given this novel role, we here review the literature for studies of mast cell involvement in the context of chronic GVHD. While there are few publications on this topic, the papers excellently characterized a niche for mast cells in chronic GVHD. These findings may be extended to other fibrosing diseases in order to better target mast cells or their mediators for treatment of fibrotic disease.

Sign in / Sign up

Export Citation Format

Share Document